CBMG shows strong data in early CART trials
This article was originally published in Scrip
Executive Summary
You may also be interested in...
China's CBMG Aims For Large-Scale CAR-T Capacity
CBMG exec Tony Liu looks to differentiate CAR-T offerings partly based on ability to produce at a large scale in China, at a standard that matches the US.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.